Health Care
Amplia Therapeutics Limited (ATX)
Amplia Therapeutics Limited is an Australian clinical-stage biotechnology company focused on developing novel treatments for cancer and fibrosis. The company is advancing small molecule inhibitors, including AMP945 (a FAK inhibitor) and AMP880 (a p38 MAPK inhibitor), with lead programs targeting pancreatic cancer and idiopathic pulmonary fibrosis.
Market Cap
A$67M
Shares on Issue
N/A
Price Chart
AI Analysis
Amplia Therapeutics is a clinical-stage biotechnology firm with a market capitalisation of A$67 million, positioning it as a highly speculative investment primarily driven by its drug development pipeline. Its lead candidate, AMP945, a Focal Adhesion Kinase (FAK) inhibitor, is currently in Phase 1 and Phase 2 clinical trials for challenging indications like pancreatic cancer and idiopathic pulmonary fibrosis (IPF), which represent significant unmet medical needs. As a pre-revenue company, its financial performance is characterised by R&D expenditure, with value creation entirely dependent on successful clinical outcomes and future commercialisation.
The growth outlook for Amplia is intrinsically tied to the progression and success of its clinical trials for AMP945 and AMP880. Key catalysts include upcoming data readouts from its ongoing Phase 2 pancreatic cancer trial and further advancement in its IPF program, which could validate its therapeutic approach and attract potential pharmaceutical partners. The strategic direction involves advancing these compounds through later-stage clinical development, seeking regulatory approvals, and exploring out-licensing or collaboration opportunities to fund commercialisation, given its small market capitalisation.
Bull Case
- • Positive Phase 2 clinical trial results for AMP945 in pancreatic cancer or idiopathic pulmonary fibrosis, demonstrating significant efficacy and safety that de-risks future development.
- • Securing a lucrative licensing agreement or strategic partnership with a major pharmaceutical company for one or more of its drug candidates, providing significant non-dilutive funding and market access.
- • Successful expansion of clinical programs into additional high-value indications, broadening the market opportunity and potential revenue streams for its pipeline.
Bear Case
- • Unfavourable or inconclusive results from ongoing or future clinical trials, leading to program delays, termination, or significant re-evaluation of its drug candidates.
- • Inability to secure sufficient funding for continued R&D and clinical development without significant shareholder dilution, impacting its ability to progress trials.
- • Intense competition from larger pharmaceutical companies developing similar or superior treatments for pancreatic cancer or IPF, potentially limiting future market share.
Recent Announcements
Quarterly Activities/Appendix 4C Cash Flow Report
🚨 Price SensitiveATX, a commitments test entity on ASX, reports positive cash flow from operating activities for the quarter ending with $2.5 million in Appendix 4C of their financial statements, indicating strong operational liquidity and potential reinvestment or dividend opportunities for investors
Change in substantial holding
Narmafotinib Large-Scale Manufacture Complete
ACCENT Data Presented at 2026 ASCO GI Cancer Symposium
FAQs
What does ATX do?
Amplia Therapeutics Limited is an Australian clinical-stage biotechnology company focused on developing small molecule inhibitors for Focal Adhesion Kinase (FAK) and p38 MAPK. Their primary drug candidates, AMP945 and AMP880, are being investigated for the treatment of various cancers (like pancreatic cancer) and fibrotic diseases (such as idiopathic pulmonary fibrosis).
Is ATX a good investment?
Investing in ATX is highly speculative, characteristic of micro-cap biotechnology companies on the ASX. Its potential for significant returns is directly linked to successful clinical trial outcomes and eventual commercialisation of its drug candidates, but it carries substantial risks, including trial failures, funding challenges, and intense competitive pressures in the biopharmaceutical sector.
What drives ATX's share price?
The share price of ATX is primarily driven by announcements related to its clinical trial progress, particularly positive or negative data readouts for AMP945 and AMP880, regulatory milestones (e.g., approvals for trial progression), securing new funding, and potential partnership or licensing agreements with larger pharmaceutical companies.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.